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Introduction
Infection with human immuno-deficiency virus type 1 (HIV) is an
important health concern globally but especially in South Africa,
which has the highest number of people living with HIV/AIDS
(PLWHA).1 HIV is known to cause adverse neurological sequelae
(also known as “neuroAIDS”) in a substantial proportion of
individuals. Despite improved survival and quality of life
following the use of highly active anti-retroviral therapy (HAART),
neuroAIDS remains prevalent. In this review, we describe the
neurobiology of dementia associated with HIV. In particular, we
describe the process of neuroinvasion, subsequent
neurodegeneration and treatments. We further aim to address
how the sub-epidemic of neuroAIDS may impact individuals and
services in South Africa and suggest strategies for approaching
this problem. 
NeuroAIDS remains prevalent, with as many as 60% of PLWHA
going on to develop some form of HIV associated neurocognitive
disorder (HAND) in their lifetime.2 Furthermore nearly 90% of
individuals have autopsy evidence of neuropathology. Neuro-
invasion is likely to occur early in the course of HIV infection
following dissemination of HIV into lymphoid tissues and cells.3
The blood brain barrier not only limits ongoing passage of HIV
into the central nervous system (CNS) following this early peak in
viral load, but also acts as a barrier to drug penetration.4 The
active infection of CNS microglial cells results in the development
of a neurotoxic inflammatory cascade, which involves primarily
the sub-cortical white matter and striatum.5 Neurocognitive
dysfunction follows the disruption of these circuits, while neuronal
apoptosis produces cortical atrophy.6 Early response to HAART is
probably associated with a rapid suppression of acute neuro-
inflammation (an “encephalopathy” syndrome), while delayed
improvement may occur following immune reconstitution and
restoration of white matter.7
Numerous clinical variables are now known to be associated
with the development of HIV-D, including low CD4 cell count and
late stage disease.7 These are especially relevant in South Africa
where the epidemic is greatest and HAART coverage is yet
incomplete. The abuse of methamphetamine not only increases
HIV risk behaviour, but is independently associated with
neurotoxicity.8,9While the use of HAART has resulted in a dramatic
reduction in the incidence of HIV-D, PLWHA with milder HAND do
not qualify for treatment. Mild neurocognitive disorder may be a
predictor of HIV-D, or at least is associated with neuropathological
changes of HIV encephalitis.10 Non-HAART treatments including
the use of lithium and memantine have been studied but results
are not robust enough to warrant widespread use.8,11 In a
resource-limited setting such as South Africa, broad screening for
HIV-D should be routine, and the use of HAART in PLWHA who
have demonstrable neurocognitive disorder should be strongly
considered. The implications at an individual, community and
societal level of untreated or persistent neurocognitive disorders in
large numbers of individuals are substantial.
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Prevalence of HIV dementia: epidemiology and
challenges
HAND remains prevalent despite HAART and clinical
characteristics may be different. Prior to the widespread use of
HAART, infection with HIV resulted in HIV-D in about 15% of
individuals.12 Less severe forms of HAND were found in about 30-
60% of PLWHA.12,13 The advent of HAART has substantially altered
the nature of these disorders, although they do persist.2,14
Specifically, HAART has reduced the incidence of HIV-D, but with
longer life span, the prevalence appears to be increasing.7,15 Not
only does this persistence suggest either ongoing neurotoxocity,
but it has implications for PLWHA who may be employed and/or
need to adhere to HAART. In addition, the clinical presentation of
HIV-D has changed6, and it has been suggested that the
subcortical features previously thought to be characteristic, may
be less prominent.16 As experience in the neuropsychological
features of HAND has grown, it has become more apparent that
cortical deficits occur frequently. 
More recently, efforts to predict the neurocognitive response to
HAART have intensified. Currently it is thought that people who
initiate HAART prior to severe immunosuppression and achieve
plasma viral suppression17, CSF viral suppression4 and who use
CSF penetrating regimens accrue the most benefit.4,18 In South
Africa, home to the largest number of PLWHA, and despite one of
the biggest anti-retroviral rollout programmes internationally,
PLWHA still enter treatment late, if at all. Reasons include limited
access to HAART, confusing government and media messaging
regarding treatment, and socio-cultural issues (such as belief
systems regarding the causes of HIV). Accordingly, the profile of
this group of individuals resembles a pre-HAART cohort, with a
high incidence of HIV-D. The only local study of community
prevalence of HIV-D, conducted in the Western Cape reported a
rate of 23.5% of HIV-D according to the HIV Dementia Scale.19 This
compares to the rate found in a study in Uganda, where the
prevalence was 31%.20
In addition to the lateness of presentation of PLWHA, clade-
specific differences may contribute to the development of HAND.
HIV subtype (or clade) B is predominant in North America and
Europe, while clade C is found in about 90% of South
Africans.21,22 The question of whether viral clade is responsible
for differences in HAND has not been well-studied in clinical
populations. For instance, the neurovirulence of HIV clade C has
been associated with less severe forms of neurocognitive
impairment in some studies, but with equally deleterious effects
in others.23-25 Variability has been attributed to differences in the
dicysteine motif within the neurotoxic region of B-Tat, producing
a greater degree of Tat-induced apoptosis.26,27 However, other
viral proteins, such as gp120, may be as neurotoxic. The clade
sequence, levels of proviral DNA and tat protein, together with
their impact on neuropsychological functions and neuro-imaging
findings, is the subject of a study currently being conducted by
our group. 
Neuro-invasion and compartmentalisation
Neuro-invasion probably occurs early in HIV infection, and is
associated with dissemination of HIV into lymphoid tissues, which
include the CD4 helper cells and circulating monocytes.3 All five
main types of cell in the CNS are susceptible to the effects of
infection, but it is thought that only perivascular macrophages and
microglia are actively or productively infected.28 These cells are
derived from bone marrow. Both are immune-competent in the
CNS, with microglia arising from the mesoderm- as such they
bear receptors related to the mononuclear phagocytic system.29
In the resting state they are branched, while in the activated state,
they are rounded or “amoeboid”.28 Active or productive infection
implies that HIV is constantly being produced from the cell
surface, while non-productive infection implies that HIV DNA is
incorporated into host cell, but not actively extruded. This latter
type of infection, together with the restricted nature of the blood-
brain barrier has led to the idea that the CNS is a “sanctuary” site
or reservoir of HIV infection. The blood brain barrier is a
selectively permeable membrane formed by a continuous cellular
barrier with tight junctions. The passage of circulating immuno-
competent cells into the CSF is tightly regulated, as is that of
drugs. 
A number of theories of neuro-invasion have been proposed,
but it seems likely that the majority of invasion arises from the
passage of HIV inside penetrating circulating macrophages
(“Trojan Horse theory”) and from transcytosis- a process of HIV
being actively transported through endothelial cells.30 Perivascular
macrophages are probably the cell line most infected and are also
readily replenished from the circulating peripheral population.31
These cells, together with some microglia, fuse to make up the
multi-nucleated giant cells (MNGC) which are the hallmark of HIV-
encephalitis.28 HIV encephalitis is the underlying
neuropathological correlate of HIV-D. MNGC express CD14 and
CD15 receptors, and these are noted on neuropathological
examinations.32
Following early CNS invasion, HIV probably re-enters the CNS
throughout the course of infection during periods of either high
viral load or systemic illness.28 Despite this, phylogenetic
reconstruction has suggested that HIV derived from various sites
in the CNS in an individual more closely resembles its own
sequences, than HIV derived from peripheral tissues.33 In addition,
unproductive infection of cell lines other than microglia and
macrophages suggests that genetic drift of HIV may be small.
These ideas again have led credence to the notion of the CNS as a
sanctuary site.
While most PLWHA have evidence of neuroAIDS, few will
develop frank clinical features. This might be explained by certain
host factors (such as genetic predisposition) and the differing
neuropathogenicity of HIV. One possible mechanism is differing
“fusogenic” potential. In the CNS, cells bearing the chemokine
receptor CCR5, as well as CD4, are prone to being fused into
MNGC. Highly neuropathogenic forms of HIV might require lower
levels of expression of these proteins, possibly leading to more
rapid and/or greater MNGC formation.34 Furthermore, certain HIV
strains might evolve into separately neuropathogenic strains
through the development of envelope glycoproteins which lower
the need for host CCR5 and CD4 receptors. 
There has been conflicting data on whether the viral load of
HIV in the CSF (as opposed to the periphery) is associated with
greater rates of HAND. Some studies have established that
improvement in neuropsychological function is correlated with
both high CNS penetration of HAART, as well as lower CSF viral
loads.4 A more recent study reported that while penetrating
HAART regimens were correlated with lower CSF viral loads,
these regimens resulted in poorer neuropsychological
performance.35 The relevance of the penetration of anti-retrovirals
is explained below. It must be noted that in the public sector in
South Africa, there is access to only a limited number of these
agents. 
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Mechanisms of neuro-degeneration
Neurodegeneration follows a breakdown in the usual interplay
between neuroprotection and neurotoxicity. These involve
interactions between various protective and toxic host compounds
(such as nerve growth factors and glutamate) and the effect of the
inflammatory process invoked by HIV. An understanding of the
role of CNS chemokines and neurotransmitters has begun to shed
light on possible mechanisms of HIV neurotoxicity. Chemokines
are cellular cytokines secreted in the CNS and which play various
roles including cell migration, differentiation, activation and
proliferation. These processes are constantly occurring. Two main
families of chemokines are especially relevant to HIV: α- and β-
chemokines.28 α-chemokines (also known as CXC family
chemokines) are all expressed in brain, mainly by neurons. The
activated CXC receptor increases intra-cellular calcium, and may
be key to excitotoxic damage.36 In contrast, β- chemokines (CCR
family chemokines) are only weakly expressed in brain. Despite
being weakly expressed, certain β- chemokines play a crucial
role in the development of HAND- these include monocyte
chemoattractant protein-1 (MCP-1). Higher levels are thought to
predict HIV-D over time.7 Other members of the β- chemokine
group may be neuroprotective, such as CCL4, which protects
neurons from gp120 induced apoptosis.36 It can then be seen that
when HIV infects and activates CD14/16 bearing cells, pro-
inflammatory cytokines are increased, leading to the development
of both MNGC and related glial and neuronal cell damage.
Two main theories of HIV-associated neurodegeneration
have been proposed. The direct injury hypothesis posits that
neuronal injury occurs directly through the effect of toxic HIV
proteins - gp120 and tat protein in particular - or through virus-
host interactions, whereby gp120 activates glutamate receptors
or TNF expression.37 In the “bystander” effect hypothesis,
damage occurs due to immune activation out of keeping with
levels of HIV in the CNS. This amplification arises out of
chemokine activation, the inflammatory activation of uninfected
cells and the migration of infected T-cells into the CNS following
chemo-attraction.38
The result of either direct or bystander effects is the
neuropathological entity known as HIV encephalitis. This entity is
now established to underlie well defined clinical HIV-D.10,39 In this
process, the activation of inflammatory chemokines and cytokines,
including TNF and nitric oxide synthase, leads to the production of
free radicals, which in turn leads to astrocyte apoptosis.40
Astrocytes play a key role in the removal of excitatory amino acids
from synapses, leading to a loss of the
neuroprotection/neurodegeneration balance. High levels of
inflammation and neurotransmitter dysregluation may lead to
clinical features of “encephalopathy”, while neuronal apoptosis
and degradation of white matter may lead to less reversible
deficits characterised by clinical slowing and subcortical effects.
The role of transcriptional transactivator (tat), a toxic viral
protein bears mention. Tat has been associated with neuronal
nuclear toxicity, alteration of blood brain barrier tight junctions and
the upregulation of pro-inflammatory cytokines.41 It has been
found that tat expression differs between HIV clades, and further
proposed that a defect in the dicysteine motif in tat in clade C
leads to lower levels of neurotoxicity.42 The implications are that in
regions where clade C is predominant, such as South Africa, lower
rates of HAND might be expected. Recent work in India, where
clade C is also predominant has not supported this idea. Rates of
HAND comparable to regions where clade B occurs, was reported
in a clinical sample.25 A large study into potential clade differences
is underway by our group. 
Clinical mediators of HIV dementia
A number of clinical factors are associated with the development
of HIV-D, and are reviewed in this section, with a particular focus
on their relevance to SA. These include the presence of
neurological impairment, the abuse of methamphetamine,
depression, female gender, low CD4 count and advancing
age.7,43-45
Substance abuse and dependence are linked to both the
acquisition of HIV, as well as to compounded neurocognitive
effects. The use of intravenous opiates, especially heroin has been
associated with the epidemic in North America, and to the co-
infection with hepatitis C. In South Africa, heroin use is fairly
restricted, although it has the potential to grow.46 In addition,
hepatitis C is thought to be very uncommon in South Africa, as
reported by one published study in Kwazulu Natal.47 The effect of
methamphetamine (MA) on both HIV risk behaviour and
neuropsychological outcomes is increasingly being studied, and
is of especial relevance locally. In a sample of more than 4500
adolescents at Cape Town schools, 12-13% had used MA at least
once, and MA was associated with high risk sexual behaviour.9
There is now good evidence for the deleterious effect of MA on
neuropsychological function.48 It has been proposed that when
MA abuse and HIV co-exist, additive neurotoxic effects, such as
increased ischaemic events and microglial activity may occur.8
The implications for South Africa where MA abuse is problematic
are enormous. 
Also of relevance to South Africa, is that the majority of PLWHA
attending clinics are women, and again, that many present with
late stage HIV/AIDS. The preponderance of women is a feature
that differentiates the Southern African epidemic from the global
one. There are some well known gender effects in
neuropsychiatry, with depression being more common in
women.49 As depression is commonly co-morbid with HAND, a
greater burden of disease in South Africa might be expected.
There is also substantial evidence that advancing age is
associated with a greater vulnerability to developing HAND, and
that this may be aggravated by the use of protease inhibitor
containing regimens.8 As with persons with Alzheimer’s dementia,
the amyloid protein has been implicated. Specifically, high levels
of β-amyloid have been observed in HIV neuropathology, as well
as increases in amyloid precursor protein and gamma secretase.
Tat may inhibit an amyloid degrading enzyme.8With the largest
HIV epidemic in the world, and the accordingly large numbers of
PLWHA entering treatment, we will face an ageing population with
these co-factors. 
Pharmacotherapy of HIV-D
Conceptually, the approach to treatment of HIV-D could be
considered from either a preventive or curative view. Drug
treatments can then be considered to be either directly anti-
retroviral, or adjuvant. Current WHO guidelines recommend the
use of HAART when either CD4 cell counts fall below 200, or a
stage 4 disease-defining illness is present. Among these
conditions is HIV encephalopathy. Once HIV-D is established, it
may be difficult to reverse neuronal loss. This raises two central
issues regarding the treatment of HIV-D: first, whether the brain is
a long term reservoir of HIV, and therefore if ongoing low grade
neuro-inflammation is occurring; and second, whether less severe
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forms of HAND either predict or progress to HIV-D. We will now
address each of these issues.
First, regarding whether the brain is a reservoir for HIV, there
has been much interest in the issue of the penetration of
antiretrovirals through the blood brain barrier. The ability of these
agents to pass into the brain, depending on their protein-binding,
molecular size and lipophilicity has been categorised into a “CNS
Penetration Effectiveness” (CPE) rank system.50 In this system,
anti-retroviral drugs are categorised into groups according to the
above criteria, with scores of 0.5, 1 and 2 being assigned to the
three groups. The nucleotide/nucleoside reverse transcriptase
inhibitors lamivudine and stavudine, for example, have a rank
score of 0.5. Of the non-nucleotide/nucleoside reverse
transcriptase inhibitors, nevirapine has a score of 1 and efavirenz
0.5. These drugs are the first line treatments in South Africa. While
several studies have shown that regimens with a relatively high
CPE rank (>2) resulted in better neurocognitive outcomes4, it is
not well known whether these regimens may produce
neurotoxicity by virtue of their penetration, whether the benefits
will persist, or if the HAART-related improvements to date have
been observed in individuals with poor baseline
neuropsychological performance or worse levels of
immunosuppression. Long term studies which examine both the
neurocognitive profile, CPE rank, as well as potential measures of
antiretroviral neurotoxicity will be needed to resolve these issues.
In a well known study, the addition of abacavir to an existing
HAART regimen was not associated with improved neurocognitive
outcomes.7 First line treatments in South Africa achieve acceptable
CPE ranks scores of between 1.5 and 2. Using a nevirapine-based
regimen, a score of 2 is reached by adding the rank scores of
lamivudine (0.5), stavudine (0.5) and nevirapine (1). 
Second, whether or not less severe forms of HAND result in, or
progress to HIV-D, are less clear. Different patterns of HIV-D have
now been proposed.15 It is suggested that some more acute and
fulminant forms may be more sensitive to treatments. Nonetheless,
only a small proportion of individuals will recover complete
neuropsychological function. If, however, HAART could be initiated
at higher CD4 counts, where less severe HAND is present, it is
possible that progression to less reversible deficits may be
prevented. Once HIV-D is present, effective HAART regimens
should be used in the first instance. Prospective studies of these
issues are sorely needed. 
The issue of antiretroviral toxicity has been addressed to a
limited extent in the literature, and is based on theories of
systemic toxicity, scanty magnetic resonance imaging (MRS)
studies, and in vitro evidence.51-53 This type of antiretroviral
neurotoxicity is independent of the phenomenon of neuroIRIS
(immune reconstitution syndrome), which is thought to be rare but
may result in worsening neurocognitive function despite HAART
use.54 NeuroIRIS may occur from between two and six weeks of
HAART, and reflects an inflammatory response following cellular
immune reactivation. IRIS is most consistently associated with
opportunistic infections (OI’s), such as Cryptococcus, tuberculosis
or JC-virus. In a small number of individuals, clinical neurological
deterioration occurs in the absence of OI’s, and is thought to
reflect a direct HIV-related immune response. 
Adjuvant treatments for HIV-D are less well established.
Treatment trials of known drugs such as memantine, an N-methyl-
D-asparate (NMDA) receptor antagonist, and lithium, a complex
mood stabiliser with glycogen synthase kinase-3 (GSK-3) function,
have been conducted with some promising results.11,55While
lithium may not be an ideal agent in South Africa, and particularly
in PLWHA, due its narrow therapeutic index, its beneficial effects
may be considered as therapeutic possibilities for other drugs.
Putative treatments, based on theories of HIV neurotoxicity include
chemokine receptor blockers, anti-oxidants, caspase inhibitors
and entry inhibitors, but any novel agent would need to penetrate
the blood brain barrier. 
Outcomes in HIV-D
The effective use of HAART has clearly been associated with a
significant reduction in the disease burden of HIV-D, as noted
above. The incidence of HIV-D has decreased substantially.7 In
untreated HIV-D the mean survival is about six months.56With
HAART, this has increased to two years, even in PLWHA with low
CD4 counts at baseline.57 Given that more than 20% of individuals
in primary care in the Western Cape have HIV-D, there are
significant implications for care.19
Nath and colleagues have proposed a number of subtypes of
HIV-D that have emerged in the HAART era, including a subacute
progressive type, a chronic inactive type, a chronic active type and
a reversible type.15 Other groups have reported “reversibility” or
“treatment response” in about 30% of PLWHA with HIV-D.58 The
converse is true that more than half have persistent deficits. This
means that on the one hand, a substantial number of PLHWA with
HIV-D will improve, and that the use of HAART is imperative, but
also that a larger number will require additional treatment
support. The implications for PLWHA who are economically or
socially active are enormous. To date, there are no published
cohort studies in South Africa, and this is needed. 
Approaches to detection, treatment and research in
resource-limited settings
Given that South Africa has the largest HIV epidemic in the world,
and that despite putative clade differences in neurotoxicity, it is
likely that a substantial proportion of individuals entering late
stage HIV/AIDS will develop HIV-D. Our approach should be
three-fold:
(1) Wide-spread screening programmes:
This will involve the use of screening tools for HIV-D being
integrated into primary health care. This is in order to detect
covert cases of HIV-D in busy clinics, where awareness of milder
HIV-D may be low. Several instruments exist, including the HIV
Dementia Scale and the Brief Cognitive Neuroscreen.59,60 A brief
tool that has been validated for use in Uganda, and that can be
taught to non-neurologist staff, is the International HIV Dementia
Scale (IHDS).61 Using a cut-off score of 10, the IHDS has a
sensitivity and specificity of 80% and 55% respectively. The
integration of the IHDS will involve training in its use, and
information regarding what to do with positive screens. At clinics,
where more extensive neuropsychological testing is not available,
patients who screen positive may be evaluated by more
experienced clinicians on a referral basis, and then initiated on
HAART. Additional treatment support and follow-up should be
considered. Where additional neuropsychological resources are
available, referral may be an option. We recommend the use of a
test battery containing tests of the following domains: attention and
concentration, verbal memory, psychomotor function and
executive function. Tests within these domains may include the
digit symbol coding test for attention, the Hopkins auditory verbal
learning test for verbal memory, the grooved pegboard test for
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psychomotor speed, and the color trails tests 1 and 2 for executive
function. These tests are widely used and are readily taught to
technical staff with a minimum of necessary equipment.
(2) Consideration of offering HAART to individuals with higher
CD4 counts 
There is debate as to whether HAART should be started in PLWHA
with higher CD4 counts. What is known, is firstly, that mild
neurocognitive disorders (MND) are common, occurring in about
20-30% of PLWHA, depending on disease stage.13 Secondly, the
presence of MND correlates with neuropathological changes
similar to HIV-D.39 Thirdly, the presence of MND is likely to produce
significant functional impairment.62Whether or not MND predicts
progression to HIV-D is less clear. We propose that PLWHA with
documented MND and functional impairment are at risk of this
deterioration, and should be initiated on HAART. Prospective
cohort studies are needed to define the outcomes more clearly.
(3) Prospective cohort treatment effects studies
To date, there have been no published cohort treatment effect
studies in South Africa, and relatively few in Africa. Studies of
PLWHA entering ARV care should be conducted with a view to
describing the course and progression of neuropsychological
impairment, the impact on function, and the effect of anti-
retrovirals on cognition. Careful clinical characterisation may
further allow for the development of predictive variables and
potential biomarkers of HIV-D. In this way, a greater understanding
of potential risk factors may be developed. The effect of anti-
retrovirals on cognition is receiving greater attention and these
studies should carefully document these.15
Conclusion
The involvement of the CNS in HIV- known as “neuroAIDS”- has
profound implications in South Africa where the largest number of
infected people lives. Several clinical implications emerge from
this review. Screening for HAND should be routinely performed in
all individuals entering care, and in those with higher CD4 counts
in whom a neurocognitive disorder is suspected. They should be
followed up in order to describe the course and impact of
neuroAIDS. In this way, we can begin to address the massive
burden that dementia-associated with HIV infection poses.
Locally relevant research directions should include
investigations into either “mechanisms” or “treatments”.
Prospective cohorts in South Africa should be studied, with a view
to gathering not only data on neurocognitive problems and their
course, but also the underlying host-viral interactions, such as
clade-specific differences. Treatment programme research needs
to consider ways of addressing the burden of disease of
neurocognitive disorders, and may involve studies of
epidemiology, but also of providing supportive and therapeutic
approaches to individuals with neurocognitive problems. The
problem of HIV dementia will not abate with widespread HAART,
and novel solutions to address this burden are urgently needed. 
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